WO2009045083A3 - Combination therapy for neuroprotection - Google Patents

Combination therapy for neuroprotection Download PDF

Info

Publication number
WO2009045083A3
WO2009045083A3 PCT/KR2008/005841 KR2008005841W WO2009045083A3 WO 2009045083 A3 WO2009045083 A3 WO 2009045083A3 KR 2008005841 W KR2008005841 W KR 2008005841W WO 2009045083 A3 WO2009045083 A3 WO 2009045083A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination therapy
damage
neuroprotection
present
pyruvoyl
Prior art date
Application number
PCT/KR2008/005841
Other languages
French (fr)
Other versions
WO2009045083A2 (en
Inventor
Sung-Hwa Yoon
Ja-Kyeong Lee
Ho-Joon Park
Young-Gyun Shin
Hae-Un Lee
Seung-Woo Kim
Hyun-Ji Kim
Original Assignee
S H Pharma Ltd
Sung-Hwa Yoon
Ja-Kyeong Lee
Ho-Joon Park
Young-Gyun Shin
Hae-Un Lee
Seung-Woo Kim
Hyun-Ji Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020080097093A external-priority patent/KR101047387B1/en
Application filed by S H Pharma Ltd, Sung-Hwa Yoon, Ja-Kyeong Lee, Ho-Joon Park, Young-Gyun Shin, Hae-Un Lee, Seung-Woo Kim, Hyun-Ji Kim filed Critical S H Pharma Ltd
Priority to US12/681,680 priority Critical patent/US20100216749A1/en
Priority to JP2010527895A priority patent/JP2010540624A/en
Publication of WO2009045083A2 publication Critical patent/WO2009045083A2/en
Publication of WO2009045083A3 publication Critical patent/WO2009045083A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to combination therapy of a pyruvoyl derivative and an anti -oxidant, which is characterized by significant increase of the activity of microglia, inhibition of brain tissue damage by the activation of inflammatory cytokines, improvement of motor skill and recovery effect of neuronal damage. Compared to single treatment with each, this present invention provides a continuous high neuroprotective effect even after 6 hours from the onset of damage.
PCT/KR2008/005841 2007-10-05 2008-10-03 Combination therapy for neuroprotection WO2009045083A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/681,680 US20100216749A1 (en) 2007-10-05 2008-10-03 Combination Therapy for Neuroprotection
JP2010527895A JP2010540624A (en) 2007-10-05 2008-10-03 Combination therapy for neuroprotection

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2007-0100351 2007-10-05
KR20070100351 2007-10-05
KR1020080097093A KR101047387B1 (en) 2007-10-05 2008-10-02 Combination Therapy to Protect Cranial Nerves
KR10-2008-0097093 2008-10-02

Publications (2)

Publication Number Publication Date
WO2009045083A2 WO2009045083A2 (en) 2009-04-09
WO2009045083A3 true WO2009045083A3 (en) 2009-05-28

Family

ID=40526851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/005841 WO2009045083A2 (en) 2007-10-05 2008-10-03 Combination therapy for neuroprotection

Country Status (1)

Country Link
WO (1) WO2009045083A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101646701B1 (en) * 2009-12-29 2016-08-08 주식회사 지엔티파마 Therapeutic use of ethylamino-benzoic acid derivative
RU2657820C1 (en) * 2017-03-13 2018-06-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ 4-(4-acetoxybenzoylamino)butanoylglycine, which has a cerebroprotective action in cerebral ischemia
US11700934B2 (en) * 2021-02-01 2023-07-18 Jean Paul Laurent Toothbrush with replacement toothbrush heads stored in handle

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHO IK-HYU ET AL.: "Ethyl pyruvate attenuates kainic acid-induced neuronal cell death in the mouse hippocampus", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 84, no. 10, 15 November 2006 (2006-11-15), pages 1505 - 1511 *
COMO P G ET AL.: "'A controlled trial of fluoxetine in nondepressed patients with Huntington's disease'", MOVEMENT DISORDERS, vol. 12, no. 3, May 1997 (1997-05-01), pages 397 - 401 *
DE MARCHI N ET AL.: "'Fluoxetine in the treatment of Huntington's disease'", PSYCHOPHARMACOLOGY, vol. 153, no. 2, 1 January 2001 (2001-01-01), pages 264 - 266 *
YU YOUNG-MI ET AL.: "Inhibition of the cerebral ischemic injury by ethyl pyruvate with a wide therapeutic window", STROKE, vol. 36, no. 10, 1 September 2005 (2005-09-01), pages 2238 - 2243 *

Also Published As

Publication number Publication date
WO2009045083A2 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
SI2430022T1 (en) 1,2,4-TriazoloŠ4,3-aĆpyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
PL1888548T3 (en) Quinoline derivative for the treatment of retinal diseases
GEP20125635B (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2009146216A3 (en) Antioxidant inflammation modulators: novel derivatives of oleanolic acid
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
WO2007100617A3 (en) Imidazole-based compounds, compositions comprising them and methods of their use
WO2006023452A3 (en) Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
PL1761266T3 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
EP1755654A4 (en) Methods and systems for treatment of neurological diseases of the central nervous system
EP2963031A3 (en) Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
CL2009000696A1 (en) Polysubstituted compounds derived from 2-aryl-6-phenyl-imidazo [1,2-a] pyridines; preparation procedure; intermediate compounds; pharmaceutical composition; and its use for the treatment and prevention of neurodegenerative diseases, brain trauma and epilepsy, psychiatric diseases, inflammatory diseases, among others.
WO2005074375A3 (en) Heparanase inhibitors and uses thereof
WO2010088414A3 (en) Subunit selective nmda receptor potentiators for the treatment of neurological conditions
SI1830843T1 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
ZA200907575B (en) C3b antobodies and methods for the prevention and treatment of complement associated disorders
WO2005089504A3 (en) Methods for the treatment of synucleinopathies
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
SI2432798T1 (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivative, methods for the production thereof and use thereof for treating diseases
EP3906043A4 (en) Methods and compositions for the treatment of fabry disease
PT1998730T (en) Novel support system for treatment and prevention of diseases of the veins
WO2007135026A3 (en) Substituted pteridines as therapeutic agents
WO2006128029A3 (en) Production of osteoclasts from adipose tissues
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
TN2012000092A1 (en) Therapeutic agent for mood disorders
WO2007112121A3 (en) Tetracycline compounds and methods of treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08835469

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010527895

Country of ref document: JP

Ref document number: 12681680

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03.08.2010)

122 Ep: pct application non-entry in european phase

Ref document number: 08835469

Country of ref document: EP

Kind code of ref document: A2